Outcomes after primary or adjuvant radiotherapy for salivary gland carcinoma

Figures & data

Table 1. Patient, tumor and treatment characteristics.

Characteristics	Total no. of patients (N = 291)	No. of patients w/adjuvant RT (n = 224)	No. of patients w/primary RT (n = 67)
Sex
Women	123 (42%)	101 (45%)	22 (33%)
Men	168 (58%)	123 (55%)	45 (67%)
Major tumor site
Parotid	136 (47%)	129 (58%)	7 (10%)
Submandibular	25 (9%)	24 (11%)	1 (1%)
Minor tumor site
Oral cavity	49 (17%)	33 (15%)	16 (24%)
Oropharynx	23 (8%)	7 (3%)	16 (24%)
Paranasal sinus	22 (8%)	12 (5%)	10 (15%)
Nasal cavity	16 (5%)	8 (4%)	8 (12%)
Other	10 (3%)	8 (4%)	2 (3%)
Nasopharynx	7 (2%)	2 (<1%)	5 (7%)
Larynx	3 (1%)	1 (<1%)	2 (3%)
Histology
Adenoid cystic carcinoma	109 (37%)	71 (32%)	38 (57%)
High-grade mucoepidermoid carcinoma	64 (22%)	55 (25%)	9 (13%)
High-grade adenocarcinoma	60 (21%)	45 (20%)	15 (22%)
Carcinoma expleomorphic adenoma	19 (7%)	18 (8%)	1 (1%)
Low-grade mucoepidermoid carcinoma	12 (4%)	10 (4%)	2 (3%)
Acinic cell carcinoma	10 (3%)	10 (4%)	0 (0%)
Low-grade adenocarcinoma	9 (3%)	7 (3%)	2 (3%)
Other*	8 (3%)	8 (4%)	0 (0%)
Peripheral Nerve Invasion
Clinical	67 (23%)	43 (19%)	24 (36%)
Microscopic	76 (26%)	76 (34%)	–
None	148 (51%)	105 (47%)	43 (64%)
Resection status
Negative margin	76 (34%)	76 (34%)	–
Microsopic disease	131 (58%)	131 (58%)	–
Macrosopic disease	14 (6%)	14 (6%)	–
Tumor classification
T1	61 (21%)	56 (25%)	5 (7%)
T2	89 (31%)	76 (34%)	13 (19%)
T3	38 (13%)	31 (14%)	7 (10%)
T4	103 (35%)	61 (27%)	42 (63%)
Nodal classification
N0	224 (77%)	169 (75%)	55 (82%)
N1	18 (6%)	14 (6%)	4 (6%)
N2	47 (16%)	40 (18%)	7 (10%)
N3	2 (1%)	1 (<1%)	1 (1%)
Overall stage
I	52 (18%)	47 (21%)	5 (7%)
II	66 (23%)	59 (26%)	7 (10%)
III	41 (14%)	34 (15%)	7 (10%)
IVA	100 (34%)	78 (35%)	22 (33%)
IVB	32 (11%)	6 (3%)	26 (39%)
Surgery
None	63 (22%)	–	63 (94%)
Primary site	148 (51%)	148 (66%)	–
Primary site and neck dissection	76 (26%)	76 (34%)	–
Neck dissection	4 (1%)	–	4 (6%)
Radiotherapy
Radiotherapy alone	67 (23%)	–	67 (6%)
Postoperative radiotherapy	209 (72%)	209 (93%)	–
Preoperative radiotherapy	15 (5%)	15 (7%)	–
Adjuvant chemotherapy
No	282 (97%)	220 (98%)	62 (93%)
Yes	9 (3%)	4 (2%)	5 (7%)

* Poorly differentiated carcinoma (2), myoepithelial carcinoma (3), lymphoepithelioma (1), basaloid carcinoma (1), oncocytic carcinomas (1).

Figure 1. Local control rates after surgery and adjuvant radiotherapy (RT), RT alone, and for the overall group.

Figure 2. Local-regional control rates after surgery and adjuvant radiotherapy (RT), RT alone, and for the overall group.

Figure 3. Distant metastasis-free survival rates after surgery and adjuvant radiotherapy (RT), RT alone, and for the overall group.

Figure 4. Cause-specific survival rates after surgery and adjuvant radiotherapy (RT), RT alone, and for the overall group.

Figure 5. Overall survival rates after surgery and adjuvant radiotherapy (RT), RT alone, and for the overall group.